Jeffrey Wolf, MD

Washington University; St. Louis, Missouri, A.B., 1968, Chemistry
University of Illinois Medical Center, Chicago, IL, M.D., 1972
University of California, San Diego, Intern, 1972-1973, Internal Medicine
University of California, San Diego, Residency, 1973-1974, Internal Medicine
University of California, San Diego, Residency, 1975-1976, Internal Medicine
Fred Hutchinson Cancer Research Center, Seattle, Washington, Fellowship, January-February, 1977, Bone Marrow Transplantation
University of California San Francisco, San Francisco, Fellowship, 1976-1979, Hematology/Oncology

• 1979-1982
  Staff Physician, City of Hope National Medical Center, Duarte, California, Hematology and Bone Marrow Transplantation
• 1982-2007
  Director of Stem Cell Transplantation Program, Practice of Hematology and Oncology, Alta Bates Summit Medical Center, Berkeley, California
• 2007-present
  Clinical Professor of Medicine, Division of Hematology/Oncology, University of California, San Francisco, California
• 2007-2010
  Director, Clinical Research, Division of Hematology/Oncology, University of California, San Francisco, California
• 2007-present
  Director, Myeloma Program, Division of Hematology/Oncology, University of California, San Francisco, California

• 1968-1972
  Bamberger Scholarship, University of Illinois, School of Medicine

• Forman, S.J., Farbstein, M.J., Scott, E.P., Wolf, J.L., Spruce, W.E., Fahey, J.L., Nademanee, A. and Blume, K.G.: Prevention and therapy for graft-vs-host disease. N. Engl. J. Med. 307:376-377, 1982.
• Blume, K.G., Spruce, W.E., Krance, R.A., Rosen, R. B., Forman, S.J., Farbstein, M.J., Wolf, J.L., Scott, E.P., Hecht, T. and Fahey, J.L.: Bone marrow transplantation for acute lymphoblastic leukemia. N. Engl. J. Med. 306:610, 1982.
• Forman, S.J., Spruce, W.E., Farbstein, M.J., Wolf, J.L., Scott, E.P., Nademanee, A.P., Fahey, J.L., Hecht, T., Zaia, J.A., Krance, R.A., Findley, D.O. and Blume, K.G.: Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia. Blood 61:439-442, 1983.
• Scott, E.P., Forman, S.J., Spruce, W.E., Krance, R.A., Farbstein, M.J., Wolf, J.L., Nademanee, A.P., Fahey, J.L., Hecht, T. and Blume, K.G.: Bone marrow ablation followed by allogeneic bone marrow transplantation for patients with high risk acute lymphoblastic leukemia during completion remission. Transplantation Proceedings 15:1395-1396, 1983.
• Rybicki, A.C., Heath, R., Wolf, J.L., Lubin, B. and Schwartz, R.S.: Deficiency of protein 4.2 in erythrocytes from a patient with a Coombs negative hemolytic anemia: Evidence of a role of protein 4.2 in stabilizing ankyrin on the membrane. Journal Clinical Investigation 81:893-901, 1988.
• Linker, C.A., Ries, C.A., Damon, L.E., Rugo, H.S., Wolf, J.L.: Autologous bone marrow transplantation for acute myeloid leukemia using Busulfan plus Etoposide as a preparative regimen. Blood, 81:311-318, 1993.
• Lienert-Weidenbach, K., Valiante, N.M., Brown, C., White, C., Johnston-Dow, L., McGinnis, M., Krausa, P., Lakes, D. M., Wolf, J. L., Blume, K.G., Parham, P.: Mismatches for two major and one minor histocompatibility antigen correlate with a patient's rejection of a bone marrow graft from a serologically HLA-identical sibling. Biology of Bone Marrow Transplantation 2(5):255-60, November 1997.
• Linker, C. A., Ries, C.A., Damon, L.E., Rugo, H.S., Wolf, J.L.: Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplantation 22, 865-872, 1998.
• McGhee, E.M., Cohen, N.R., Wolf, J.L., Ledesma, C.T., and Cotter, P.D.: Monosomy 16 as the sole abnormality in myeloid malignancies. Cancer Genetics and Cytogenetics 118: 163-166, 2000.
• Govberg, I.J., Wolf, J.L., and Cotter, P.D.: Trisomy 4 and double minutes in acute myeloid leukemia: Further evidence that double minutes can occur as the primary cytogenetic abnormality. Cancer Genetics and Cytogenetics 121:212-215, 2000.
• Linker, C.A., Ries, C.A., Damon, L.E., Sayre, P., Navarro, W., Rugo, H.S., Rubin, A., Case, D., Crilley, P., Topolsky, D., Brodsky, I., Zamkoff, K., Wolf, J.L., Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Remission. Biology of Blood and Marrow Transplantation 6:50-57, 2000.
• Damon, L.E., Wolf, J.L., Rugo, H.S., Gold, E., Zander, A.R., Cassidy, M., Cecchi, G., Cohen, N., Irwin, D., Tracy, M., Ries, C.A., Linker, C.A.: High-Dose Chemotherapy for Breast Cancer: Improved Results in Patients with >10 Involved Axillary Lymph Nodes. Bone Marrow Transplantation 26:3, 257 268, 2000
• Damon, L.E., Wolf, J.L., Rugo, H.S., Gold, E., Zander, A.R., Cassidy, M., Cecchi, G., Cohen, N., Irwin, D., Tracy, M., Ries, C.A., Linker, C.A. High-Dose Chemotherapy (CTM) for Breast Cancer. Bone Marrow Transplantation 26:257-268, 2000.
• Jagannath, S., Durie, B.G., Wolf, J., Camacho, E, Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D., Crowley, J. Bortezomib Therapy Alone and in Combination with Dexamethasone for Previously Untreated Symptomatic Multiple Myeloma. British Journal of Hematology 129(6):776-83, 2005.
• Wolf, J., Richardson, P., Schuster, M., LeBlanc, A., Walters, I., Battleman. D. Utility of Bortezomib Retreatment in Relapsed or Refractory Multiple Myeloma Patients: a Multicenter Case Series. Clinical Management of Hematology and Oncology 6(10): 755-760, 2008.